2023 World Conference on Lung Cancer (Posters)-P2.31. Missed Opportunities for Lung Cancer Personalized Medicine in a Brazilian Public Healthcare Service

P2.31. Missed Opportunities for Lung Cancer Personalized Medicine in a Brazilian Public Healthcare Service - PDF(Slides)

Back to course

Pdf Summary

Precision oncology has revolutionized the way lung cancer treatments are tailored to individual patients. However, limited resources and logistical challenges hinder its adoption in developing countries. This study aimed to assess the missed opportunities for precision oncology in lung cancer management, focusing on early and advanced non-small cell lung cancer (NSCLC) patients. The electronic medical records of 174 patients were reviewed, and 103 patients with NSq NSCLC were included. The evaluation of missed opportunities was carried out at each stage of the process. <br /><br />For patients with early-stage NSCLC, 80% were lost in the first stage of access to genomic testing. Among patients with advanced disease, 32% were classified as unfit for testing due to short life expectancy. Among those who had access to the examination, 9% were lost due to insufficient sample. Only one participant underwent testing for all recommended biomarkers, resulting in a loss of 98% of patients. When considering EGFR and ALK tests, 46% were lost, and considering only EGFR tests, 6% were lost.<br /><br />Regarding targeted therapy, 40% of patients with actionable gene mutations did not receive treatment. However, for patients with EGFR-mutated tumors, only 8% were lost due to lack of access to anti-EGFR therapy.<br /><br />The results highlight the need to improve access to genomic testing, ensure adequate samples for analysis, and expand the testing panel for recommended biomarkers. Barriers to the adoption of targeted therapy for patients with actionable gene mutations, apart from EGFR, were also identified.<br /><br />In conclusion, the findings emphasize the challenges in implementing personalized medicine for lung cancer, especially in early-stage disease. Improving access to testing and targeted therapy is crucial for enhancing patient outcomes.

Asset Subtitle

Pedro Aguiar Jr

Meta Tag

Speaker Pedro Aguiar Jr

Topic Global Health, Health Services & Health Economics: Real World Data

Keywords

precision oncology

lung cancer treatments

individual patients

developing countries

missed opportunities

genomic testing

biomarkers

targeted therapy

access to testing

patient outcomes